Montpellier-based SeqOne Acquires Cambridge-based Congenica

Together, they will create the world’s largest dedicated genomics software provider, serving over 160 laboratories in more than 30 countries.

"The rapid pace of personalised medicine demands continuous investment in software innovation and deep specialisation," said Martin Dubuc, CEO of SeqOne. "By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market – a global leader in clinical genomics since the landmark 100,000 Genomes Project."

Founded in 2012, Congenica brings deep clinical expertise, serving 25+ private and public labs, including NHS Genomics Hubs and national initiatives like Genomics England and Hong Kong’s Genomic Programme.

SeqOne, launched in 2017, offers an AI-powered platform for genomic analysis, supporting oncology, rare diseases, and infectious disease applications.

Read Also - US-based Beroe Acquires London-based Startup Forestreet

The acquisition combines SeqOne’s NGS analysis technology with Congenica’s clinical decision support and interpretation services. Together, they aim to turn complex genomic data into fast, actionable insights—accelerating rare disease diagnoses and enabling personalised cancer treatments.

With sequencing costs falling sharply, data generation is no longer the challenge—interpretation is. This deal directly addresses that bottleneck, advancing the future of precision medicine.

"Congenica has been an instrumental partner to Genomics England, particularly in advancing rare disease diagnosis through their robust platform for clinical whole genome analysis," said Dr Richard Scott, Chief Executive Officer at Genomics England. "We look forward to continuing this important work with the combined expertise of the SeqOne team to deliver benefits for patients."

The acquisition follows a year of rapid growth for SeqOne, during which the company reportedly doubled its revenue and expanded from three to 30+ countries.

It also builds on the April acquisition of Life & Soft, which added multi-omics and virology capabilities. Backed by a €20M funding round, SeqOne is executing its strategy to consolidate a fragmented market and create the leading software operating system for clinical genomics.

SeqOne will ensure seamless service and support for all Congenica customers, who will benefit from a broader, integrated product portfolio. The company will also maintain a strong UK presence at the Wellcome Sanger Institute.

"The Board of Congenica is proud of the immense impact our technology has had on healthcare since our inception," said Dr Andy Richards CBE, Chairman of Congenica. "We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally."

About Congenica

Congenica, founded from pioneering work at the Wellcome Sanger Institute and UK NHS is a digital health company transforming genomic data into precision medicine. Its CE-marked platform unifies analysis across rare diseases, cancer, pharma and pathogens, supporting healthcare providers, patients, and global institutions with scalable, automated diagnostic solutions.